Logo-jrhs
J Res Health Sci. 21(3):e00520. doi: 10.34172/jrhs.2021.57

Review Article

Factors for the Primary Prevention of Breast Cancer: A Meta-Analysis of Prospective Cohort Studies

Jalal Poorolajal 1, 2, 3, Fatemeh Heidarimoghis 1, *, Manoochehr Karami 1, 4, Zahra Cheraghi 1, 2, Fatemeh Gohari-Ensaf 1, Fatemeh Shahbazi 1, Bushra Zareie 1, Pegah Ameri 1, Fatemeh Sahraei 1
1Department of Epidemiology, School of Public Health, Hamadan University of Medical Sciences, Hamadan, Iran
2Modeling of Noncommunicable Diseases Research Center, Hamadan University of Medical Sciences, Hamadan, Iran
3Research Center for Health Sciences, Hamadan University of Medical Sciences, Hamadan, Iran
4Social Determinants of Health Research Center, Hamadan University of Medical Sciences, Hamadan, Iran
* Correspondence: Fatemeh Heidarimoghis (MSc) Tel: +98 81 38380090 Fax: +98 81 38380509 E-mail: heidarifateme180@gmail.com

Abstract

Background: This report provided the effect of 15 preventable factors on the risk of breast cancer incidence.

Study design: A systematic review and meta-analysis.

Methods: A detailed research was conducted on PubMed, Web of Science, and Scopus databases in January 2020. Reference lists were also screened. Prospective cohort studies addressing the associations between breast cancer and 15 factors were analyzed. Between-study heterogeneity was investigated using the χ2, τ2, and I2 statistics. The probability of publication bias was explored using the Begg and Egger tests and trim-and-fill analysis. Effect sizes were expressed as risk ratios (RRs) with 95% confidence intervals (CIs) using a random-effects model.

Results: Based on the results, out of 147,083 identified studies, 197 were eligible, including 19,413,702 participants. The RRs (95% CI) of factors associated with breast cancer were as follows: cigarette smoking 1.07 (1.05, 1.09); alcohol drinking 1.10 (1.07, 1.12); sufficient physical activity 0.90 (0.86, 0.95); overweight/obesity in premenopausal 0.92 (0.82, 1.03) and postmenopausal 1.18 (1.13, 1.24); nulliparity 1.16 (1.03, 1.31); late pregnancy 1.37 (1.25, 1.50); breastfeeding 0.87 (0.81, 0.93); ever using oral contraceptive 1.00 (0.96, 1.05); ever using estrogen 1.13 (1.04, 1.23); ever using progesterone 1.02 (0.84, 1.24); ever using estrogen/progesterone 1.60 (1.42, 1.80); ever taking hormone replacement therapy 1.26 (1.20, 1.32); red meat consumption 1.05 (1.00, 1.11); fruit/vegetable consumption 0.87 (0.83, 0.90); and history of radiation therapy, based on single study 1.31 (0.87, 1.98).

Conclusions: This meta-analysis provided a clear picture of several factors associated with the development of breast cancer. Moreover, the useful information in this study may be utilized for ranking and prioritizing preventable risk factors to implement effective prevention programs.

Keywords: Breast neoplasms, Risk factors, Behavior, Nutrition, Meta-analysis

Copyright

© 2021 The Author(s); Published by Hamadan University of Medical Sciences.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Introduction

Breast cancer is the most commonly occurring cancer in women, regardless of race or ethnicity, impacting over 2 million women worldwide annually, responsible for over 600,000 deaths in 2018 1 . According to the biennial report of the American Cancer Society, the breast cancer incidence rate had increased slightly by 0.3% per year 2 . Several factors, such as genetic characteristics, lifestyle factors, and medical conditions, may play a role in the development of breast cancer. The risk factors for breast cancer can be divided into two categories, namely (a) fixed risk factors that may contribute to the development of breast cancer, however, cannot be changed, such as age, female gender, genetic characteristics 3 , immunologic biomarkers 4 , racial or ethnic characteristics 5 , family history 6 , and late menopause 7 ; and (b) modifiable risk factors that play a role in the development of breast cancer and can be changed, such as alcoholic beverage consumption 8 , cigarette smoking 9 , physical inactivity 10 , high body mass index (BMI) 11 , high dietary fat 12 , and dietary fiber intake 13 . These factors are largely modifiable and preventable, and therefore, can be considered when designing effective prevention programs.

Efforts to improve screening programs and the early detection and treatment of breast cancer are important; nevertheless, it is of priority to take action to address preventable factors that play an important role in the development of breast cancer. Some measures, such as ranking and prioritizing the risk factors that contribute to the development of breast cancer and implementing prevention programs, can reduce the incidence of breast cancer and prevent thousands of new cases each year. Effective intervention strategies and prevention programs need a comprehensive understanding and a clear picture of the contributing factors that promote breast cancer. To the best of our knowledge, no comprehensive systematic review has yet been conducted to address all the potential preventable factors playing a pivotal role in the development of breast cancer. This meta-analysis was performed to address the associations between breast cancer and 15 factors that might be potentially modifiable and preventable, and consequently, might provide an opportunity to be addressed in prevention programs aimed to reduce the incidence of breast cancer.


Methods

The eligibility criteria in this study were based on population, intervention, comparison, outcomes, and study design (PICOS). Accordingly, the women having any of the 15 preventable factors mentioned below were included in the exposure group and those without any of the 15 preventable factors mentioned below in the unexposed group. The outcome was considered breast cancer and the prospective cohort studies were reviewed.

Eligibility criteria

The outcome of interest was having pathologically confirmed breast cancer, of any type (i.e., ductal or lobular carcinomas), among the general population, regardless of age, gender, race, ethnicity, and geographical region. The exposures of interest are listed below:

  • Cigarette smoking (current/former smokers versus nonsmokers)

  • Drinking alcohol (current/former drinkers versus non-drinkers)

  • Physical activity (sufficient versus insufficient)

  • Body mass index (overweight/obese versus normal weight)

  • Parity (nulliparous versus primiparous/multiparous)

  • Late pregnancy (≥30 years versus <30 years)

  • Breastfeeding (ever versus never, or ≥6 months versus <6 months, or ≥12 months versus <12 months, or ≥24 months versus <24 months)

  • Ever using oral contraceptive (OCP) (yes versus no)

  • Ever using estrogen (yes versus no)

  • Ever using progesterone (yes versus no)

  • Ever using estrogen/progesterone (yes versus no)

  • Ever taking hormone replacement therapy (HRT) (yes versus no)

  • Intake of red meat (highest intake versus lowest intake)

  • Intake of fruit/vegetable (highest intake versus lowest intake)

  • History of radiation therapy (yes versus no)

A BMI of 18.5-24.9 kg/m2 was classified as normal weight, 25.0-29.9 kg/m2 as overweight, and ≥ 30.0 kg/m2 as obese. At least 30 minutes of moderate- to vigorous-intensity physical activity per day (or 150 minutes per week) was considered sufficient for adults 14 . Pregnancy over the age of 30 is considered high-risk 15 . Accordingly, reproductive ages of > 30 were considered late pregnancy in this study. The duration of breastfeeding is recommended for at least 6 months continued up to 2 years of age or longer 16 . Accordingly, various periods of breastfeeding, including ≥ 6, ≥ 12, and ≥ 24 months were considered in this research. The consumption of at least five total servings (400 grams) of fruit and vegetables per day is recommended 17 . However, the majority of the included studies did not report fruit and vegetable consumption according to the recommendations of the World Health Organization. Therefore, the highest intake versus the lowest intake of fruit and vegetables were compared in the present study. There is no universal recommendation for red meat consumption. In this respect, the highest intake versus the lowest intake of red meat was also compared in this research.

Prospective cohort studies addressing the association between breast cancer and any of the above factors were included in the meta-analysis, irrespective of their language and publication date and the participants' nationality, race, gender, and age. Wherever reported, full adjusted forms of risk ratio (RR) controlled was used for at least one or more potential confounding factors.

Information sources and search

A detailed search was conducted on PubMed, Web of Science, and Scopus databases in January 2020. The reference lists of the included studies were also explored. The search process was performed based on the following keywords: (Breast cancer or Breast neoplasms or Breast malignancy or Breast tumor) and (Smoking or Cigarette or Tobacco or Cigar or Alcohol or Ethanol or Exercise or Physical activity or Obese or Obesity or Overweight or Body mass index or BMI or Pregnancy or Breastfeeding or Contraceptive or Hormone or Estrogen or Progesterone or Fruit or Vegetables or Red meat or Radiation)

Study selection

The search results of all databases were combined using EndNote, and duplicates were deleted. Afterward, six authors (i.e., FH, FS, BZ, PA, FS, and FG) formed three two-person groups. Each group screened the titles and abstracts of one-third of the search results separately and independently and excluded ineligible studies. The full texts of potentially relevant studies were retrieved for further evaluation.

Data extraction

The data from the relevant studies were extracted by 6 authors (i.e., FH, FS, BZ, PA, FS, and FG) using an electronic data collection form prepared in Stata (StataCorp, College Station, TX, USA).

Methodological quality

The Newcastle-Ottawa Scale (NOS) 18 was used to assess the methodological quality of the included studies. Based on this scale, a maximum of 9 stars were assigned to each study. Studies that received 7 or more stars were labeled high-quality; otherwise, studies were classified as low-quality.

Heterogeneity and publication bias

The heterogeneity across studies was examined using the Chi-square (χ2) test 19 and tau-square (τ2) test and quantified by the I2 statistic 20 . According to the I2 value, heterogeneity was classified as low (<50%), moderate (50-74%), or high (≥75%). The possibility of publication bias was explored by the Egger 21 and Begg 22 tests and the trim-and-fill method 23 .

Summary measures

The effect measure of choice was the RR with 95% confidence intervals. The results were reported based on a random-effects model 24 . The data were analyzed at a significance level of 0.05 using Stata software (version 14.2; StataCorp, College Station, TX, USA) and Review Manager software (version 5.3).

Sensitivity analysis

If the between-study heterogeneity was moderate to high (I2≥50%), the source of heterogeneity was investigated using the MetaPlot Stata command based on the sequential algorithm 25-27 .


Results

Description of studies

In total, 147,083 studies were identified, including 139,649 studies obtained by searching the electronic databases in January 2020 and 7,434 articles identified by searching the reference lists of the included studies. After excluding duplicates and ineligible studies, 197 studies with 19,413,702 participants (Table 1) were included in the meta-analysis ().

jrhs-21-e00520-g001
Figure 1. Flow of information through the various phases of the systematic review

Table 1. Characteristics of the included studies (sorted by authors’ names)
Row 1 St author, year Country Age (year) Study design Effect size Adjustment Sample Size NOS Quality
1 Adebamowo, 2005USA20-46Prospective cohortRate RatioAdjusted90,6388- High quality
2 Agurs-Collins, 2009USA21-69Prospective cohortRate RatioAdjusted50,7789- High quality
3 Al-Ajmi, 2018UK56.3Prospective cohortRisk RatioAdjusted273,4679- High quality
4 Albrektsen, 2005Norway20-74Prospective cohortRate RatioUnadjusted1,700,0006- Low quality
5 Al-Delaimy, 2004USA25-42Prospective cohortRate RatioAdjusted116,6718- High quality
6 Alipour, 2019Iran40-75Nested case-controlRate RatioAdjusted4998- High quality
7 Anderson, 2018UK40-69Prospective cohortRate RatioAdjusted262,1959- High quality
8 Arslan, 2014USA60.05Nested case-controlRate RatioAdjusted9987- High quality
9 Arthur, 2017USA21-85Nested case-controlRate RatioAdjusted1,0528- High quality
10 Azam, 2018Denmark50-69Prospective cohortHazard RatioAdjusted4,5018- High quality
11 Baglietto, 2010Australia27-81Case-cohortRisk RatioUnadjusted1,0549- High quality
12 Baglietto, 2011Australia40-69Prospective cohortRate RatioAdjusted20,9678- High quality
13 Bakken, 2011Europe58.1Prospective cohortRisk RatioAdjusted133,7449- High quality
14 Barlow, 2006USA35-84Prospective cohortRisk RatioAdjusted2,392,9989- High quality
15 Bassett, 2013Melbourne27-80Case-cohortRisk RatioAdjusted20,7568- High quality
16 Bellocco, 2016Sweden56.1Prospective cohortHazard RatioAdjusted19,1969- High quality
17 Beral, 2011UK56.6Prospective cohortRisk RatioAdjusted1,129,0258- High quality
18 Bergkvist, 1989Sweden≥35Prospective cohortRisk RatioAdjusted23,2446- Low quality
19 Bjerkaas, 2013Norway44Prospective cohortHazard RatioAdjusted302,8658- High quality
20 Bjørge, 2010Norway-Sweden-Austria44Prospective cohortRisk RatioAdjusted287,3208- High quality
21 Bravi, 2018Italy41-79Nested case-controlRate RatioAdjusted13,2128- High quality
22 Brinton, 2013Israel31.1Prospective cohortHazard RatioAdjusted87,4039- High quality
23 Brinton, 2014USA50-71Prospective cohortHazard RatioAdjusted190,8278- High quality
24 Buring, 1987USA30-55Prospective cohortRisk RatioAdjusted33,3356- Low quality
25 Butler, 2010Singapore45-74Prospective cohortRate RatioAdjusted34,0288- High quality
26 Butt, 2014Sweden57.23Prospective cohortRisk RatioAdjusted14,0929- High quality
27 Campa, 2011USA-Europe62.39Nested case-controlRate RatioAdjusted20,4687- High quality
28 Catsburg, 2015Canada40-59Prospective cohortHazard RatioAdjusted89,8359- High quality
29 Cerhan, 1998USA65-102Prospective cohortRisk RatioAdjusted1,8067- High quality
30 Chen, 2002USA50-74Nested case-controlRate RatioAdjusted1,3977- High quality
31 Chen, 2016Taiwan≥35Prospective cohortHazard RatioAdjusted1,393,9859- High quality
32 Chlebowski, 2013USA50-79Prospective cohortHazard RatioAdjusted41,4498- High quality
33 Cho, 2006USA26-46Prospective cohortRisk RatioAdjusted90,6599- High quality
34 Clavel-Chapelon, 2007France40-65Prospective cohortRisk RatioAdjusted80,3778- High quality
35 Cohen, 2013USA40-79Nested case-controlRate RatioAdjusted2,7307- High quality
36 Colditz, 2003USA25-42Prospective cohortRisk RatioAdjusted116,6719- High quality
37 Cottet, 2009France52.2Prospective cohortRate RatioAdjusted65,3749- High quality
38 Couto, 2013Sweden30-49Prospective cohortRisk RatioAdjusted49,2589- High quality
39 Cross, 2007USA50-71Prospective cohortRate RatioAdjusted500,0009- High quality
40 Cust, 2009Sweden50-69Nested case-controlRate RatioAdjusted1,1227- High quality
41 Dai, 2009China40-70Nested case-controlRate RatioAdjusted1,2888- High quality
42 Dallal, 2007USA20-79Prospective cohortRisk RatioAdjusted110,5999- High quality
43 Dartois, 2016France42-72Prospective cohortRisk RatioAdjusted67,6348- High quality
44 Diallo, 2018France≥35Prospective cohortRate RatioAdjusted61,4768- High quality
45 Diergaarde, 2008USA50-76Nested case-controlRate RatioAdjusted9756- Low quality
46 Dorgan, 1994USA35-68Prospective cohortRisk RatioAdjusted2,3218- High quality
47 Dorgan, 2010Columbia31-56Nested case-controlRate RatioAdjusted2669- High quality
48 Dossus, 2014Europe-Prospective cohortHazard RatioAdjusted322,9889- High quality
49 Dumeaux, 2004Norway30-70Prospective cohortRisk RatioAdjusted86,9489- High quality
50 Dumeaux, 2005France40-64Prospective cohortRisk RatioAdjusted68,6707- High quality
51 Egan, 2002USA30-55Prospective cohortRisk RatioAdjusted78,2068- High quality
52 Egeberg, 2008Denmark50-64Prospective cohortRate RatioAdjusted24,6978- High quality
53 Eisen, 2008USA58.2Nested case-controlRate RatioAdjusted4726- Low quality
54 Elebro, 2014Sweden-Prospective cohortHazard RatioAdjusted17,0359- High quality
55 Ellingjord-Dale, 2017Norway50-69Nested case-controlRate RatioAdjusted29,1629- High quality
56 Epplein, 2009USA45-75Nested case-controlRate RatioAdjusted8217- High quality
57 Fabre, 2007France51.8Prospective cohortRisk RatioAdjusted73,6648- High quality
58 Fagherazzi, 2015France40-65Prospective cohortHazard RatioAdjusted66,4819- High quality
59 Falk, 2014USA55-74Prospective cohortHazard RatioAdjusted54,5629- High quality
60 Farhat, 2011USA50-79Case-cohortRisk RatioAdjusted9039- High quality
61 Farvid, 2014USA26-45Prospective cohortRate RatioAdjusted88,8049- High quality
62 Feigelson, 2004USA50-74Prospective cohortRate RatioAdjusted97,7868- High quality
63 Ferrucci, 2009USA55-74Prospective cohortRate RatioAdjusted52,1589- High quality
64 Fourkala, 2014UK64Prospective cohortHazard RatioAdjusted92,8347- High quality
65 Fournier, 2014bFrance59.68Prospective cohortHazard RatioAdjusted78,3539- High quality
66 Fraser, 1997USA55Prospective cohortRisk RatioAdjusted34,1988- High quality
67 Friedenretch, 1993CanadaNo dataNested case-controlRate RatioAdjusted1,7018- High quality
68 Fuhrman, 2012UK55-74Nested case-controlRate RatioAdjusted7008- High quality
69 Fung, 2005USA30-55Prospective cohortRisk RatioAdjusted11,7008- High quality
70 Gapstur, 1999USA55-69Prospective cohortRisk RatioAdjusted41,8378- High quality
71 Garland, 1999USA25-42Prospective cohortRate RatioAdjusted116,6718- High quality
72 Gaudet, 2014USANo dataProspective cohortRisk RatioAdjusted28,9659- High quality
73 Genkinger, 2013USA21-69Prospective cohortRate RatioAdjusted52,0629- High quality
74 Gertig, 2006Australia40-69Prospective cohortHazard RatioAdjusted24,4798- High quality
75 Goodman, 1997JapanNo dataProspective cohortRisk RatioAdjusted22,2009- High quality
76 Gram, 2005Norway-Sweden30-50Prospective cohortRisk RatioAdjusted102,0989- High quality
77 Gram, 2015USA45-75Prospective cohortHazard RatioAdjusted83,3009- High quality
78 Gram, 2016Norway34-70Prospective cohortHazard RatioAdjusted130,0539- High quality
79 Ha, 2007USA22-92Prospective cohortHazard RatioAdjusted56,0429- High quality
80 Hanaoka, 2005Japan40-59Prospective cohortRisk RatioAdjusted27,3989- High quality
81 Hankinson, 1997USA30-55Prospective cohortRisk RatioAdjusted121,7007- High quality
82 Hiatt, 1988USANo dataProspective cohortRisk RatioAdjusted68,6747- High quality
83 Holmberg, 1995Sweden40-75Nested case-controlRate RatioAdjusted7287- High quality
84 Holmes, 2003USA30-55Prospective cohortRisk RatioAdjusted88,6478- High quality
85 Horn, 2013Norway28-73Prospective cohortHazard RatioAdjusted58,4269- High quality
86 Horn, 2014bNorway48-64Prospective cohortHazard RatioAdjusted21,5328- High quality
87 Horn-Ross, 2004USA<85Prospective cohortRisk RatioAdjusted103,4609- High quality
88 Inoue-Choi, 2016USA24-43Prospective cohortRate RatioAdjusted193,7429- High quality
89 Jick, 1980USA31-55Prospective cohortRisk RatioAdjusted40,5316- Low quality
90 Jones, 2017UK47Prospective cohortHazard RatioAdjusted102,9278- High quality
91 Jordan, 2009Thailand28-51Nested case-controlRate RatioAdjusted9035- Low quality
92 Kabat, 2007USA40-59Prospective cohortRate RatioAdjusted49,6549- High quality
93 Kabat, 2010USA-UK-CanadaNo dataNested case-controlRate RatioAdjusted1,3578- High quality
94 Kawai, 2010Japan40-64Prospective cohortHazard RatioAdjusted24,0648- High quality
95 Kerlikowske, 2010USA56.4Prospective cohortRisk RatioAdjusted587,3698- High quality
96 Kim, 2012USA45-75Nested case-controlRate RatioAdjusted1,4267- High quality
97 Kim, 2017Korea≥30Prospective cohortRisk RatioAdjusted5,0469- High quality
98 Kojima, 2017Japan70-79Prospective cohortRate RatioAdjusted23,1728- High quality
99 Komaroff, 2016USA≥50Nested case-controlRate RatioAdjusted1587- High quality
100 Kops, 2018Brazil40-69Nested case-controlRate RatioAdjusted2167- High quality
101 Kotsopoulos, 2010USA30-55Prospective cohortRate RatioAdjusted107,7598- High quality
102 Krishnan, 2013Australia40-69Prospective cohortHazard RatioAdjusted14,4418- High quality
103 Lahmann, 2007Europe20-80Prospective cohortHazard RatioAdjusted218,1696- Low quality
104 Lambe, 1998Sweden<65Nested case-controlRate RatioAdjusted8,2056- Low quality
105 Lando, 1999USA55.5Prospective cohortRisk RatioAdjusted5,7618- High quality
106 Larsen, 2010Denmark50-64Nested case-controlRate RatioAdjusted1,6187- High quality
107 Larsson, 2009Sweden60.8Prospective cohortRate RatioAdjusted61,4339- High quality
108 Lecarpentier, 2012France40.4Prospective cohortRisk RatioAdjusted1,3378- High quality
109 Lee, 2006USA45-75Prospective cohortRisk RatioAdjusted55,3718- High quality
110 Lee, 2014Singapore45-74Nested case-controlRate RatioAdjusted1,6238- High quality
111 Leon, 1989UK16-59Prospective cohortRate RatioAdjusted113,2637- High quality
112 Lew, 2009USA50-71Prospective cohortRisk RatioAdjusted184,4188- High quality
113 Lin, 2008Japan40-79Prospective cohortHazard RatioAdjusted34,4019- High quality
114 Link, 2013USA≤84Prospective cohortRate RatioAdjusted91,7799- High quality
115 Lipnick, 1986USA30-55Prospective cohortRisk RatioAdjusted121,9646- Low quality
116 Liu, 2013USA25-44Prospective cohortRisk RatioAdjusted91,0059- High quality
117 Liu, 2016Taiwan45-64Prospective cohortHazard RatioAdjusted15,8638- High quality
118 London, 1989USA30-55Prospective cohortRate RatioAdjusted117,5577- High quality
119 Lowery, 2011USA>40Prospective cohortRisk RatioAdjusted208,6678- High quality
120 Lukanova, 2008Sweden30.96Nested case-controlRate RatioAdjusted5677- High quality
121 Luo, 2011USA50-79Prospective cohortHazard RatioAdjusted79,9908- High quality
122 Ma, 2010USANo dataProspective cohortRisk RatioAdjusted52,4648- High quality
123 Manjer, 2000SwedenNo dataProspective cohortRisk RatioAdjusted10,9028- High quality
124 Margolis, 2005Norway-Sweden30-49Prospective cohortRate RatioAdjusted99,5048- High quality
125 Masala, 2017Italy35-64Nested case-controlRate RatioAdjusted7717- High quality
126 Mccarty, 2012USA55-74Nested case-controlRate RatioAdjusted2,1116- Low quality
127 Mertens, 2006USA45-64Prospective cohortHazard RatioAdjusted7,9948- High quality
128 Michels, 1996USA30-55Prospective cohortRate RatioAdjusted121,7019- High quality
129 Mills, 1989bUSA55.4Prospective cohortRate RatioAdjusted20,3417- High quality
130 Missmer, 2002USA31-90Prospective cohortRate RatioAdjusted351,0419- High quality
131 Moradi, 2002Sweden25-50Prospective cohortRisk RatioAdjusted25,7787- High quality
132 Morimoto, 2002USA50-79Prospective cohortRisk RatioAdjusted85,9178- High quality
133 Nitta, 2016Japan40-79Prospective cohortHazard RatioAdjusted38,6108- High quality
134 Nyante, 2014USA50-71Prospective cohortHazard RatioAdjusted186,1509- High quality
135 Olsson, 2003Sweden25-65Prospective cohortHazard RatioAdjusted28,3789- High quality
136 Opatrny, 2008UK50-75Nested case-controlRate RatioAdjusted37,8637- High quality
137 Ozmen, 2008Turkey18-70Nested case-controlRate RatioAdjusted3,6595- Low quality
138 Pala, 2009Italy25-70Prospective cohortRate RatioAdjusted319,8269- High quality
139 Park, 2014USA45-75Prospective cohortHazard RatioAdjusted85,0899- High quality
140 Persson, 1999SwedenNo dataProspective cohortRisk RatioAdjusted10,4729- High quality
141 Phipps, 2012USA40-84Prospective cohortHazard RatioAdjusted1,054,4668- High quality
142 Pijpe, 2010Netherlands44.5Prospective cohortRisk RatioAdjusted7258- High quality
143 Pijpe, 2012France-UK-Netherlands>18Prospective cohortRisk RatioAdjusted1,9936- Low quality
144 Poosari, 2014Thailand30-69Prospective cohortHazard RatioAdjusted11,4149- High quality
145 Pouchieu, 2014France48.15Prospective cohortRate RatioAdjusted4,6847- High quality
146 Reynolds, 2004USANo dataProspective cohortHazard RatioAdjusted116,5449- High quality
147 Rice, 2016USA32-70Nested case-controlRate RatioAdjusted4,7127- High quality
148 Rintala, 2003Finland>25Prospective cohortRate RatioAdjusted10,0498- High quality
149 Risch, 1994Canada43-49Prospective cohortRisk RatioAdjusted33,0037- High quality
150 Rockhill, 1999USA30-55Prospective cohortRisk RatioAdjusted85,3648- High quality
151 Rod, 2009Denmark62Prospective cohortHazard RatioAdjusted5,0549- High quality
152 Rohan, 2000Canada40-59Case-cohortRisk RatioAdjusted56,8378- High quality
153 Romieu, 1989USA30-55Prospective cohortRisk RatioAdjusted118,2736- Low quality
154 Saxena, 2010USA60.82Prospective cohortRate RatioAdjusted56,8678- High quality
155 Schairer, 1994USA57.4Prospective cohortRate RatioAdjusted49,0177- High quality
156 Schatzkin, 1987USA25-74Prospective cohortRisk RatioAdjusted7,1889- High quality
157 Schoemaker, 2014UKNo dataNested case-controlRate RatioAdjusted6087- High quality
158 Schuurman, 1995Netherlands55-69Prospective cohortRate RatioAdjusted62,5737- High quality
159 Sellers, 1992USA55-69Prospective cohortRisk RatioAdjusted37,1057- High quality
160 Setiawan, 2009USA45-75Prospective cohortRisk RatioAdjusted84,4278- High quality
161 Shannon, 2005China50-64Prospective cohortRate RatioAdjusted1,0708- High quality
162 Shin, 2016Japan50-70Prospective cohortRate RatioAdjusted49,5529- High quality
163 Shore, 2008USA35-65Nested case-controlRate RatioAdjusted1,2247- High quality
164 Sieri, 2009Italy35-69Nested case-controlRate RatioAdjusted8378- High quality
165 Simon, 1991USA≥21Prospective cohortRisk RatioAdjusted1,9549- High quality
166 Sonestedt, 2008Sweden46-75Prospective cohortRisk RatioAdjusted15,7738- High quality
167 Sonnenschein, 1999USA35-65Prospective cohortRisk RatioAdjusted8,1578- High quality
168 Stahlberg, 2004Denmark>44Prospective cohortRisk RatioAdjusted10,8746- Low quality
169 Stahr, 2019USA18-100Prospective cohortRisk RatioAdjusted21,9319- High quality
170 Stuebe, 2009USA25-42Prospective cohortHazard RatioAdjusted60,0758- High quality
171 Suzuki, 2006Sweden64.6Prospective cohortRate RatioAdjusted51,8238- High quality
172 Taylor, 2007UK35-69Prospective cohortRate RatioAdjusted35,3729- High quality
173 Tehard, 2006France45-70Prospective cohortRate RatioAdjusted69,1168- High quality
174 Terry, 2001Sweden40-76Prospective cohortRate RatioAdjusted61,4639- High quality
175 Thomas, 2001Iceland20-81Nested case-controlRate RatioAdjusted10,4227- High quality
176 Thorbjarnardottir, 2014Iceland59.2Prospective cohortHazard RatioAdjusted16,9289- High quality
177 Thune, 1997Norway20-54Prospective cohortRisk RatioAdjusted25,6249- High quality
178 Tikk, 2015Europe54.8Nested case-controlRate RatioAdjusted6147- High quality
179 Tjønneland, 2004bDenmark50-64Prospective cohortRate RatioAdjusted23,6187- High quality
180 Trapido, 1981USA25-57Prospective cohortRisk RatioAdjusted95,5197- High quality
181 Trieu, 2017Vietnam48.09Nested case-controlRate RatioAdjusted7886- Low quality
182 Tryggvadottir, 1997Iceland18-43Nested case-controlRate RatioAdjusted1,3878- High quality
183 Tulinius, 1990IcelandNo dataProspective cohortRisk RatioAdjusted61,0405- Low quality
184 van den Brandt, 2017Netherland55-69Case-cohortRisk RatioAdjusted62,5738- High quality
185 van der Hel, 2004Netherlands20-59Prospective cohortRate RatioAdjusted4937- High quality
186 Vatten, 1992Norway20-49Prospective cohortRisk RatioAdjusted29,9819- High quality
187 Velie, 2005USA40-91Prospective cohortRate RatioAdjusted40,5598- High quality
188 Voorrips, 2002Netherlands55-69Prospective cohortRate RatioAdjusted62,5738- High quality
189 Wada, 2015Japan54.15Prospective cohortHazard RatioAdjusted15,7199- High quality
190 Wang, 2015aChina35.55Nested case-controlRate RatioAdjusted1297- High quality
191 Wang, 2015bUSA30-55Prospective cohortHazard RatioAdjusted106,0378- High quality
192 Ward, 2008UK45-75Nested case-controlRate RatioAdjusted1,1898- High quality
193 Weiderpass, 2004Norway30-49Prospective cohortRisk RatioAdjusted99,7178- High quality
194 White, 2017bUSA35-74Prospective cohortHazard RatioAdjusted50,8848- High quality
195 Willett, 1987USA34-59Prospective cohortRisk RatioAdjusted121,7008- High quality
196 Zeleniuch-jacquotte, 2012USA34-65Nested case-controlRate RatioAdjusted1,0397- High quality
197Zhang, 1999USA12-62Prospective cohortRate RatioAdjusted5,0488- High quality

NOS: Newcastle Ottawa Scale, HRT: Hormone replacement therapy, OCP: Oral contraceptive pill, PA: Physical activity

Synthesis of results

Cigarette smoking Based on 90 studies (urihttp://jrhs.umsha.ac.ir/public/site/Files/6921/1.pdfSupplementary File 1), the overall RR for smokers versus nonsmokers was 1.07 (95% CI, 1.05, 1.09). The overall effect measure showed that smoking significantly increased the risk of breast cancer by 7% (P <0.001). Between-study heterogeneity was moderate (I2=54%). The overall effect became a bit stronger (RR, 1.08; 95% CI, 1.06, 1.10; I2=42%) after performing a sensitivity analysis (Table 2).

Based on 48 studies, the overall RR for current smokers versus never smokers was 1.06 (95% CI, 1.03, 1.10). The overall effect measure showed that current smoking significantly increased the risk of breast cancer by 6% (P<0.001). Between-study heterogeneity was moderate (I2=65%). The overall effect became a bit stronger (RR, 1.09; 95% CI, 1.05, 1.13; I2=49%) after performing a sensitivity analysis.

Based on 42 studies, the overall RR for former smokers versus never smokers was 1.07 (95% CI, 1.05, 1.10). The overall effect measure showed that former smoking significantly increased the risk of breast cancer by 7% (P<0.001). Between-study heterogeneity was low (I2=29%). There was no evidence of publication bias (P=0.222 and P=0.965 based on the Begg and Egger tests, respectively)

Drinking alcohol Based on 56 studies (urihttp://jrhs.umsha.ac.ir/public/site/Files/6921/2.pdfSupplementary File 2), the overall RR for drinkers versus nondrinkers was 1.10 (95% CI, 1.07, 1.12). The overall effect measure showed that drinking significantly increased the risk of breast cancer by 10% (P<0.001). Between-study heterogeneity was moderate (I2=63%). The overall effect became slightly weaker (RR, 1.08; 95% CI, 1.06, 1.11; I2=49%) after performing a sensitivity analysis (Table 2).

Based on 46 studies, the overall RR for current drinkers versus never drinkers was 1.09 (95% CI, 1.06, 1.12). The overall effect measure showed that current drinking significantly increased the risk of breast cancer by 9% (P<0.001). Between-study heterogeneity was moderate (I2=66%). The overall effect became slightly weaker (RR, 1.08; 95% CI, 1.05, 1.10; I2=50%) after performing a sensitivity analysis.

Based on 10 studies the overall RR for former drinkers versus never drinkers was 1.22 (95% CI, 1.07, 1.39). The overall effect measure showed that former drinking significantly increased the risk of breast cancer by 22% (P<0.001). Between-study heterogeneity was low (I2=43%). There was no evidence of publication bias (P=0.997 and P=0.211 based on the Begg and Egger tests, respectively).

Table 2. Results of sensitivity analysis
Variables Before the sensitivity analysis After the sensitivity analysis
Studies χ 2 I 2 RR (95% CI) Studies χ 2 I 2 RR (95% CI)
Cigarette smoking900.00154%1.07 (1.05, 1.09)840.00242%1.08 (1.06, 1.10)
Alcohol drinking560.00163%1.10 (1.07, 1.12)530.00149%1.08 (1.06, 1.11)
Sufficient physical activity160.00163%0.90 (0.86, 0.95)150.03045%0.89 (0.85, 0.94)
Overweight/obesity520.00176%1.10 (1.05, 1.14)450.00145%1.11 (1.08, 1.15)
Nulliparity670.00197%1.16 (1.03, 1.31)600.00144%1.22 (1.18, 1.27)
Late pregnancy370.00190%1.37 (1.25, 1.50)360.00241%1.29 (1.23, 1.35)
Breastfeeding350.00182%0.87 (0.81, 0.93)320.4501%0.93 (0.91, 0.96)
Ever using oral contraceptive450.00164%1.00 (0.96, 1.05)420.00838%1.04 (1.01, 1.08)
Ever using estrogen230.00188%1.13 (1.04, 1.23)180.01046%1.09 (1.03, 1.16)
Ever using progesterone50.02067%1.02 (0.84, 1.24)30.9100%1.01 (0.94, 1.10)
Ever using estrogen/progesterone170.00195%1.60 (1.42, 1.80)80.05050%1.47 (1.37, 1.59)
Ever taking hormone replacement therapy620.00188%1.26 (1.20, 1.32)420.00150%1.27 (1.23, 1.32)
Red meat consumption220.00352%1.05 (1.00, 1.11)210.01047%1.06 (1.01, 1.12)
Fruit/vegetable consumption140.5500%0.87 (0.83, 0.90)A sensitivity analysis was not necessary.

Sufficient physical activity — Based on 16 studies (urihttp://jrhs.umsha.ac.ir/public/site/Files/6921/3.pdfSupplementary File 3), the overall RR for sufficient versus insufficient physical activity was 0.90 (95% CI, 0.86, 0.95). The overall effect measure showed that physical activity reduced significantly the risk of breast cancer by 9% (P<0.001). Between-study heterogeneity was moderate (I2=63%). The overall effect became slightly stronger (RR, 0.89; 95% CI, 0.85, 0.94; I2=45%) after performing a sensitivity analysis. There was no evidence of publication bias (P=0.677 and P=0.136 based on the Begg and Egger tests, respectively).

Body mass index — Based on 52 studies (urihttp://jrhs.umsha.ac.ir/public/site/Files/6921/4.pdfSupplementary File 4), the overall RR for overweight/obesity versus normal weight was 1.10 (95% CI, 1.05, 1.14). The overall effect measure showed that overweight/obesity significantly increased the risk of breast cancer by 10% (P<0.001). Between-study heterogeneity was high (I2=76%). The overall effect became slightly stronger (RR, 1.11; 95% CI, 1.08, 1.14; I2=49%) after performing a sensitivity analysis (Table 2). There was no evidence of publication bias (P=0.917 and P=0.105 based on the Begg and Egger tests, respectively).

The effect of body mass index on the incidence risk of breast cancer was evaluated in pre- and post-menopausal periods separately. Based on 15 studies (urihttp://jrhs.umsha.ac.ir/public/site/Files/6921/5.pdfSupplementary File 5), the overall RR for overweight/obesity versus normal weight in the premenopausal period was 0.92 (95% CI, 0.82, 1.03). The overall effect measure showed that overweight/obesity had no significant effect on the risk of breast cancer (P=0.140). Between-study heterogeneity was low (I2=50%). On the other hand, based on 24 studies (urihttp://jrhs.umsha.ac.ir/public/site/Files/6921/6.pdfSupplementary File 6), the overall RR for overweight/obesity versus normal weight during the postmenopausal period was 1.18 (95% CI, 1.13, 1.24). The overall effect measure showed that overweight/obesity significantly increased the risk of breast cancer by 18% (P<0.001).

Parity — Based on 67 studies (urihttp://jrhs.umsha.ac.ir/public/site/Files/6921/7.pdfSupplementary File 7), the overall RR for nulliparous versus primiparous/multiparous was 1.16 (95% CI, 1.03, 1.31). The overall effect measure showed that nulliparity significantly increased the risk of breast cancer by 16% (P<0.001). Between-study heterogeneity was high (I2=97%). The overall effect became slightly stronger (RR, 1.22; 95% CI, 1.18, 1.27; I2=44%) after performing a sensitivity analysis (Table 2).

The Egger test revealed no evidence of publication bias (P=0.182); however, the Begg test did indicate evidence of publication bias (P=0.001). Trim-and-fill analysis estimated 19 missing studies () and the overall effect became slightly weaker (RR, 1.08; 95% CI, 0.99, 1.17).

jrhs-21-e00520-g002
Figure 2. Trim-and-fill analysis estimating the number of possible missing studies for the association between breast cancer and nulliparity The squares represent the possible missing studies.

Late pregnancy — Based on 37 studies (urihttp://jrhs.umsha.ac.ir/public/site/Files/6921/8.pdfSupplementary File 8), the overall RR for late pregnancy of ≥30 years versus normal pregnancy of <30 years was 1.37 (95% CI, 1.25, 1.50). The overall effect measure showed that late pregnancy significantly increased the risk of breast cancer by 37% (P<0.001). Between-study heterogeneity was high (I2=90%). The overall effect became slightly weaker (RR, 1.29; 95% CI, 1.23, 1.35; I2=41%) after performing a sensitivity analysis (Table 2).

The Egger test revealed no evidence of publication bias (P=0.150); nevertheless, the Begg test did indicate evidence of publication bias (P=0.001); however, the trim-and-fill analysis estimated no missing studies.

Breastfeeding — Based on 35 studies urihttp://jrhs.umsha.ac.ir/public/site/Files/6921/9.pdfSupplementary File 9, the overall RR for breastfeeding versus no breastfeeding was 0.87 (95% CI, 0.81, 0.93). The overall effect measure showed that breastfeeding reduced significantly the risk of breast cancer by 13% (P<0.001). Between-study heterogeneity was high (I2=82%). The overall effect became slightly weaker (RR, 0.93; 95% CI, 0.91, 0.96; I2=1%) after performing a sensitivity analysis (Table 2). There was no evidence of publication bias (P=0.178 and P=0.249 based on the Begg and Egger tests, respectively).

Ever using OCP — Based on 45 studies (urihttp://jrhs.umsha.ac.ir/public/site/Files/6921/10.pdfSupplementary File 10), the overall RR for using OCP versus not using OCP was 1.00 (95% CI, 0.96, 1.05). Using OCP did not affect breast cancer (P=0.870). Between-study heterogeneity was moderate (I2=64%). The overall effect became slightly stronger and significant (RR, 1.04; 95% CI, 1.01, 1.08; I2=38%) after performing a sensitivity analysis (Table 2). There was no evidence of publication bias (P=0.417 and P=0.588 based on the Begg and Egger tests, respectively).

Ever using estrogen — Based on 23 studies (urihttp://jrhs.umsha.ac.ir/public/site/Files/6921/11.pdfSupplementary File 11), the overall RR for using estrogen versus not using estrogen was 1.13 (95% CI, 1.04, 1.23). The overall effect measure showed that using estrogen significantly increased the risk of breast cancer by 13% (P<0.001). Between-study heterogeneity was high (I2=88%). The overall effect became slightly weaker (RR, 1.09; 95% CI, 1.03, 1.16; I2=46%) after performing a sensitivity analysis (Table 2). There was no evidence of publication bias (P=0.464 and P=0.913 based on the Begg and Egger tests, respectively).

Ever using progesterone — Based on 5 studies (urihttp://jrhs.umsha.ac.ir/public/site/Files/6921/12.pdfSupplementary File 12), the overall RR for using progesterone versus not using progesterone was 1.02 (95% CI, 0.84, 1.24). The overall effect measure showed that using progesterone had no significant effect on breast cancer (P=0.820). Between-study heterogeneity was moderate (I2=67%). The overall effect became slightly weaker (RR, 1.01; 95% CI, 0.94, 1.10; I2=0%) after performing a sensitivity analysis (Table 2). There was no evidence of publication bias (P=0.293 and P=0.211 based on the Begg and Egger tests, respectively).

Ever using estrogen/progesterone — Based on 17 studies (urihttp://jrhs.umsha.ac.ir/public/site/Files/6921/13.pdfSupplementary File 13), the overall RR for using estrogen/progesterone versus not using estrogen/progesterone was 1.60 (95% CI, 1.42, 1.80). The overall effect measure showed that using estrogen/progesterone significantly increased the risk of breast cancer by 60% (P<0.001). Between-study heterogeneity was high (I2=95%). The overall effect became slightly weaker (RR, 1.47; 95% CI, 1.37, 1.59; I2=50%) after performing a sensitivity analysis (Table 2). There was no evidence of publication bias (P=0.537 and P=0.528 based on the Begg and Egger tests, respectively).

Ever taking hormone replacement therapy — Based on 62 studies (urihttp://jrhs.umsha.ac.ir/public/site/Files/6921/14.pdfSupplementary File 14), the overall RR for taking HRT versus not taking HRT was 1.26 (95% CI, 1.20, 1.32). The overall effect measure showed that taking HRT significantly increased the risk of breast cancer by 26% (P<0.001). Between-study heterogeneity was high (I2=88%). The overall effect became slightly stronger (RR, 1.27; 95% CI, 1.23, 1.32; I2=50%) after performing a sensitivity analysis (Table 2). There was no evidence of publication bias (P=0.775 and P=0.440 based on the Begg and Egger tests, respectively).

Red meat consumption — Based on 22 studies (urihttp://jrhs.umsha.ac.ir/public/site/Files/6921/15.pdfSupplementary File 15), the overall RR for the highest intake versus the lowest intake of red meat was 1.05 (95% CI, 1.00, 1.11). The overall effect measure showed that the consumption of red meat had no significant effect on breast cancer (P=0.030). Between-study heterogeneity was moderate (I2=52%). The overall effect became slightly stronger (RR, 1.06; 95% CI, 1.01, 1.12; I2=47%) after performing a sensitivity analysis (Table 2). The Begg test revealed no evidence of publication bias (P=0.108), while the Egger test did indicate evidence of publication bias (P=0.022). However, the trim-and-fill analysis estimated no missing studies.

Fruit/vegetable consumption — Based on 14 studies (urihttp://jrhs.umsha.ac.ir/public/site/Files/6921/16.pdfSupplementary File 16), the RR for the highest intake versus the lowest intake of fruit/vegetables infrequently was 0.87 (95% CI, 0.83, 0.90). The overall effect measure showed that fruit/vegetable consumption significantly reduced the risk of breast cancer by 23% (P=0.001). Between-study heterogeneity was low (I2=0%). There was no evidence of publication bias (P=0.412 and P=0.536 based on the Begg and Egger tests, respectively).

History of radiation therapy — Only one prospective cohort study 28 was found that investigated the effect of previous radiation therapy on the incidence of breast cancer. Based on the results of this study, the RR for ever-exposing to radiation therapy versus never-exposing to radiation therapy was 1.31 (0.87, 1.98). The effect measure showed that exposure to radiation therapy had no significant effect on breast cancer.

Unified overview

presents a unified overview of the associations between breast cancer and all nutritional and behavioral factors. As shown in this figure, taking HRT, using estrogen/progesterone, using estrogen, having late pregnancy, being nulliparous, consuming red meat, and being overweight/obese in the postmenopausal period were found to significantly increase the risk of breast cancer. In contrast, sufficient physical activity, fruit/vegetable consumption, and breastfeeding reduced significantly the risk of breast cancer. Meanwhile, exposure to ionizing radiation, using progesterone, using OCP, and being overweight/obese in the premenopausal period had no statistically significant effects on the risk of breast cancer.

jrhs-21-e00520-g003
Figure 3. Associations (95% CIs) between breast cancer and nutritional and behavioral factors in a single view Protective factors are shown in green (dark green, significant) and risk factors are shown in red (dark red, significant; light red, non-significant). The figures in parenthesis show the number of included studies.


Discussion

According to our findings, estrogen/progesterone uptake and late pregnancy were the first and second most powerful risk factors for breast cancer, respectively, whereas, sufficient fruit/vegetable consumption and sufficient physical activity were the first and second most powerful protective factors against breast cancer, respectively. The magnitudes of the effect measures reported in this systematic review may be used for ranking and prioritizing the relative importance of risk and protective factors. However, it should be kept in mind that these factors vary in terms of their physiological modus operandi and their units of exposure; therefore, direct comparisons are often unwarranted 29 . In other words, the mere fact that the RRs of some risk factors for breast cancer are higher than the RRs of other risk factors is not a sufficient basis for ranking and prioritizing risk factors. Instead, the prevalence of risk factors in the community is an essential criterion that needs to be taken into account when ranking and prioritizing risk factors. When the effect of a particular risk factor on the outcome of interest is strong (a high RR), however, the prevalence of that risk factor is low in the community, the overall impact of the risk factor on the disease burden in the community is low. In contrast, when a particular risk factor is common in the community, the overall impact of the factor on the outcome of interest may be tremendous even if the association between the risk factor and the outcome is not very strong (a low RR). Therefore, ranking and prioritizing the behavioral and nutritional factors affecting the risk of breast cancer depend on both the strength of the associations (the magnitude of RRs) and the prevalence of the factors in the community. Furthermore, it is impossible to consider risk or protective factors as separate elements, rather, they should be considered a collection. Risk factors facilitate the occurrence of diseases, while protective factors inhibit their occurrence. When a balance exists between risk and protective factors or when protective factors overcome risk factors, the disease will not occur. In contrast, the disease will occur when risk factors are stronger than protective factors 30 .

Our results revealed a positive association between cigarette smoking and the development of breast cancer. Ambrosone et al. conducted a meta-analysis of observational studies in 2008 and reported the effect of cigarette packs/years on breast cancer risk. They reported a dose-dependent fashion RR=1.44 (95% CI: 1.23, 1.68 for ≥20 pack/years versus never smokers) 31 . Cigarette smoke contains over 7,000 toxic chemical compounds, including human carcinogens 32 . These toxins and carcinogens can result in direct DNA damage. Since DNA controls the normal growth and function of cells, damage to DNA can alter the growth patterns of cells. These abnormal gastric epithelial cells with DNA damage can turn into cancer 33,34 .

This meta-analysis indicated that drinking alcohol increased the risk of developing breast cancer. Acetaldehyde, the first and most toxic metabolite of ethanol, is a human carcinogen and can induce DNA lesions by inhibiting DNA methylation and by interacting with retinoid metabolism 35 . DNA lesions can cause cell mutations, which can convert a normal cell into cancer 36 . Moreover, alcohol can act as an irritant and lead to mucosal damage. The damaged cells may try to repair themselves, which may cause DNA changes that can be a step toward cancer 37 .

According to our results, the risk of breast cancer of former drinkers was higher than that of current drinkers. One possible explanation for this finding is that former drinkers might be heavy drinkers who had drunk alcohol for many years; however, they were forced to quit drinking alcohol because of severe hepatobiliary and gastrointestinal complications 38 . Consistent with our findings, Key et al. performed a meta-analysis of studies addressing the association between alcohol and breast cancer in 2006. They concluded that excess risk associated with alcohol drinking was 22% (95% CI: 9%, 37%); each additional 10 g ethanol/day was associated with a risk increase by 10% (95% CI: 5%, 15%) 39 . In addition, Bagnardi et al. 40 conducted a dose-response meta-analysis to address the effect of alcohol consumption and site-specific cancer risk. Based on the results of the mentioned meta-analysis, the relative risk of female breast cancer was reported to be 1.04 (95%: 1.01, 1.07), 1.23 (95% CI: 1.19, 1.28), and 1.61 (95% CI: 1.33, 1.94) for light, moderate, and heavy drinking, respectively. Although the approach of this meta-analysis to address the effect of drinking alcohol on breast cancer risk was different from ours, its results were consistent with ours confirming that drinking alcohol can increase the risk of breast cancer.

Our results showed a positive and significant causal relationship between breast cancer and overweight and obesity as a whole. However, the effect of BMI on the incidence risk of breast cancer was different in pre- and post-menopausal periods separately. It was revealed that overweight/obesity had no significant effect on the risk of breast cancer in the premenopausal period (P<0.170); nonetheless, it had a significant impact on the postmenopausal period (P<0.001). These findings were consistent with the results of a previous meta-analysis conducted by Cheraghi et al. 11 in 2012. They reported that overweight and obesity had no significant effect on the incidence of breast cancer during the premenopausal period, whereas it might increase the postmenopausal risk of breast cancer. Evidence, based on the meta-analyses of observational studies, indicated that excess BMI not only increased the postmenopausal risk of breast cancer but also heightened the risk of gynecologic cancer in women, such as endometrial cancer 41 , cervical cancer 42 , and ovarian cancer 43 .

Based on our findings, using OCP, estrogen, progesterone, a combination of estrogen/progesterone, and HRT significantly increased the risk of breast cancer. The results of several previously conducted meta-analyses approved our findings. Steinberg et al. conducted a meta-analysis of case-control studies using community controls that analyzed the effect of conjugated equine estrogens on breast cancer. They reported that the risk of breast cancer after 10 years of estrogen use increased by at least 15% and up to 29% 44 . Based on the findings of another meta-analysis conducted by Steinberg et al., hormone replacement therapy using estradiol (with or without progestin) was associated with an increased risk of breast cancer RR=2.2 (95% CI, 1.4, 3.4) after 15 years 45 . Several mechanisms have been suggested to explain the association by which HRT increases the risk of breast cancer. The results of experimental studies showed that rigorous cell proliferation occurs upon hormonal exposure in patients with hormone receptor-positive breast cancer. Zghair et al. indicated that breast cancer type 1 susceptibility protein (BRCA1) was the predominant marker gene responsible for estrogen regulation. They reported that exposure to high levels of estrogen, as well as exposure to high levels of iron during the postmenstrual period, exerted synergistic effects on cellular proliferation in BRCA1-linked hormone-responsive breast cancer 46 . Additionally, both in vivo and in vitro investigations have been demonstrated that combination therapy with estradiol and estrogen/norethisterone increases the overexpression of proliferation of progesterone receptor membrane component 1 in breast cancer cells 47 . Furthermore, Wiebe et al. reported that progesterone metabolite 5α-pregnane stimulated breast cell proliferation and detachment, and therefore, played an important role in the development of breast cancer 48 .

The results of the present study indicated that breastfeeding decreased the risk of breast cancer by 13%, while late pregnancy significantly increased the risk of breast cancer by 40%. Consistent with our findings, Unar-Munguía recently conducted a meta-analysis in 2017 and showed that the relative risk for breast cancer in women who had breastfed exclusively was 0.72 (95% CI: 0.58, 0.90), compared to women who had never breastfed 49 . On the other hand, Namiranian et al. showed in a meta-analysis that the age of first pregnancy after 30 years was associated with an increased risk of breast cancer odds ratio=1.52 (95% CI: 1.30, 1.77) 50 . Pregnancy is associated with extensive changes to the breasts, making breast cells less likely to multiply and develop tumors. This issue explains the protective effect of pregnancy on younger women. However, after the age of 35 years, breast tissue is more likely to have accumulated cells carrying cancer-causing mutations, or clusters of abnormal cells with the potential to become cancerous. However, the important question is why the first pregnancy after age 35 increases the risk of breast cancer. The answer to this question lies in a signaling pathway called the JAK-STAT5 pathway. During pregnancy, pre-existing precancerous cells activate the PRLR-Jak2-STAT5 signaling pathway, accelerating their progression to fully cancerous cells. Blocking Jak2-STAT5 activity can reduce breast cancer risk associated with late-age pregnancy. This pathway can be blocked by various molecules, including Ruxolitinib, AG490, and C188-9 51 .

Our results indicated that sufficient physical activity significantly reduced the risk of breast cancer. Based on the findings of a meta-analysis conducted by Chen et al., there was an inverse association between physical activity and risk of breast cancer OR=0.87 (95% CI: 0.84, 0.90) 52 . Another meta-analysis conducted by Wu et al. reported a dose-response inversed relationship between physical activity and breast cancer risk. According to the results of this meta-analysis, the risk of breast cancer decreased by 2% for every 25 metabolic equivalents (MET)-h/week increment in non-occupational physical activity, 3% for every 10 MET-h/week increments in a recreational activity, and 5% for every 2 h/week increments in moderate plus vigorous recreational activity 53 . The mechanism by which physical activity reduces the risk of breast cancer is controversial. The results of empirical studies proposed that exercise-induced transient systemic acidosis will alter the in situ tumor microenvironment and delay tumor adaptation to regional hypoxia and acidosis in the later stages of carcinogenesis. Smallbone et al. demonstrated that repeated episodes of transient systemic acidosis would interrupt critical evolutionary steps in the later stages of carcinogenesis resulting in a substantial delay in the evolution of the invasive phenotype. They suggested that transient systemic acidosis might mediate the observed reduction in cancer risk associated with increased physical activity 54 .

Based on our findings, the intake of fruit and vegetable had a significant protective effect against breast cancer. The results of a meta-analysis recently conducted by Zhang et al. showed that the intake of vegetable-fruit-soybean dietary patterns could reduce the risk of breast cancer RR=0.87 (95% CI: 0.82, 0.91) 55 . Another meta-analysis conducted by Gandini et al. reported similar results. Based on the results of the mentioned meta-analysis, the relative risk of breast cancer for those who consumed vegetables was 0.75 (95% CI: 0.66, 0.85), and for those who consumed fruit was 0.94 (95% CI: 0.79, 1.11) 56 . It has been postulated that the anti-carcinogenic effects of fruits and vegetables may be attributed to the antioxidant effect of their vitamin content, especially vitamin C and beta-carotene. Antioxidants neutralize reactive oxygen free radicals, which cause DNA damage 57,58 , which in turn may result in genetic modifications and carcinogenesis ,34 .

Based on our findings, red meat consumption had a weak, yet, significant positive association with breast cancer. Farvid et al. 59 conducted a meta-analysis to address the effect of red and processed meat consumption on breast cancer incidence. They concluded that red meat consumption was associated with a 6% higher breast cancer risk (RR=1.06; 95% CI: 0.99, 1.14). The findings of another meta-analysis conducted by Guo et al. showed similar results. They reported that the relative risk of breast cancer for the highest versus the lowest consumption of red meat was 1.10 (95% CI: 1.02, 1.19) 60 . Current evidence recommends consuming no more than moderate amounts of red meat, such as beef, pork, and lamb, and eat little, if any, processed meat. The recommendation is to limit consumption to no more than about three portions per week, which are equivalent to about 350-500 grams (about 12-18 ounces) cooked weight of red meat 61 . There is strong evidence that the intake of either red or processed meat is the cause of colorectal, stomach, and breast cancers 38,62 .

This review had a few limitations and potential biases. There were some studies, mostly old, that seemed potentially eligible to be included in this meta-analysis; nevertheless, neither their full texts nor their corresponding authors were accessible. This issue might have introduced a selection bias in our results. Furthermore, some epidemiological studies that addressed the associations between breast cancer and some risk factors were excluded from the meta-analysis since they were not consistent with the inclusion criteria defined for this review. This issue might also have raised the possibility of selection bias.

Despite its limitations, this meta-analysis had three priorities over the previously conducted ones. First, many of the previous meta-analyses were carried out several years ago and needed to be updated based on current evidence. Second, in this study, 15 modifiable risk factors were examined, for some of which, no meta-analysis has been conducted before. Third, only the results of prospective cohort studies were employed that were the gold standard for observational studies with higher credibility.


Conclusion

This meta-analysis provided a clear picture of several factors playing pivotal roles in the development of breast cancer. These results are helpful and may be utilized for ranking and prioritizing preventable risk factors to implement effective interventions and community-based prevention programs. It is reemphasized that both the strength of associations and the prevalence of factors in the community should be taken into account when ranking and prioritizing breast cancer-associated factors.


Acknowledgments

These results were obtained as a part of an MSc thesis in Epidemiology. The authors would like to appreciate the Vice-Chancellor for Research and Technology of the Hamadan University of Medical Sciences, Hamadan, Iran, for approval and financial support of this study.


Conflict of interests

The authors have no conflict of interest to declare.


Funding

The Vice-Chancellor of Research and Technology, Hamadan University of Medical Sciences, funded this study (No. 9611247562). The funder had a role in the study design, data collection, analysis, publication decision, or manuscript preparation.


Highlights

  • Using estrogen/progesterone and late pregnancy are the first and second most powerful risk factors for breast cancer, respectively.

  • Sufficient fruit/vegetable consumption and sufficient physical activity were the first and second most powerful protective factors against breast cancer, respectively.

  • Ranking and prioritizing risk factors are essential for prevention programs.

  • Both the strength of association and the prevalence of risk factors are important for ranking.


References

  1. World Health Organization. Breast cancer. Geneva: WHO; 2020 [cited 15 Feb 2020]; Available from: https://www.who.int/cancer/prevention/diagnosis-screening/breast-cancer/en/.
  2. DeSantis CE, Ma J, Gaudet MM, Newman LA, Miller KD, Goding Sauer A. Breast cancer statistics, 2019. CA Cancer J Clin 2019; 69:438-51.
  3. Sifri R, Gangadharappa S, Acheson LS. Identifying and testing for hereditary susceptibility to common cancers. CA Cancer J Clin 2004; 54:309-26.
  4. Poorolajal J, Nafissi N, Akbari ME, Mahjub H, Esmailnasab N, Babaee E. Breast cancer survival analysis based on immunohistochemistry subtypes (ER/PR/HER2): a retrospective cohort study. Arch Intern Med 2016; 19:680-6.
  5. DeSantis CE, Miller KD, Goding Sauer A, Jemal A, Siegel RL. Cancer statistics for African Americans, 2019. CA Cancer J Clin 2019; 69:211-33.
  6. Eccles DM, Pichert G. Familial non-BRCA1/BRCA2-associated breast cancer. Lancet Oncol 2005; 6:705-11.
  7. Poorolajal J, Akbari ME, Ziaee F, Karami M, Ghoncheh M. Breast cancer screening (BCS) chart: a basic and preliminary model for making screening mammography more productive and efficient. J Public Health (Oxf) 2018; 40:e118-25.
  8. Shield KD, Soerjomataram I, Rehm J. Alcohol Use and Breast Cancer: A Critical Review. Alcohol Clin Exp Res 2016; 40:1166-81.
  9. Johnson KC, Miller AB, Collishaw NE, Palmer JR, Hammond SK, Salmon AG. Active smoking and secondhand smoke increase breast cancer risk: the report of the Canadian Expert Panel on Tobacco Smoke and Breast Cancer Risk (2009). Tob Control 2011; 20:e2.
  10. Lee IM, Shiroma EJ, Lobelo F, Puska P, Blair SN, Katzmarzyk PT. Effect of physical inactivity on major non-communicable diseases worldwide: an analysis of burden of disease and life expectancy. Lancet 2012; 380:219-29.
  11. Cheraghi Z, Poorolajal J, Hashem T, Esmailnasab N, Doosti Irani A. Effect of body mass index on breast cancer during premenopausal and postmenopausal periods: a meta-analysis. Plos One 2012; 7:e51446.
  12. Blackburn GL, Wang KA. Dietary fat reduction and breast cancer outcome: results from the Women's Intervention Nutrition Study (WINS). Am J Clin Nutr 2007; 86:s878-81.
  13. Mourouti N, Kontogianni MD, Papavagelis C, Panagiotakos DB. Diet and breast cancer: a systematic review. Int J Food Sci Nutr 2015; 66:1-42.
  14. World Health Organization. Global strategy on diet, physical activity and health: Fifty -seventh World Health Assembly WHA 57.17. Geneva: WHO; 2004.
  15. Health Encyclopedia. Risks of pregnancy over age 30. University of Rochester Medical Center; 2020 [cited July 09, 2020]; Available from: https://www.urmc.rochester.edu/encyclopedia/content.aspx?contenttypeid=90&contentid=P02481.
  16. Center for Chronic Disease Prevention and Health Promotion. What are the benefits of breastfeeding? Atlanta: CDC; 2020 [updated May 28, 2020; cited July 9, 2020]; Available from: https://www.cdc.gov/breastfeeding/faq/index.htm.
  17. World Health Organization. Global action plan for the prevention and control of noncommunicable diseases 2013-2020. Geneva: WHO; 2013.
  18. Wells GA, Shea B, O'Connell D, Peterson J, Welch V, Losos M, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Ontario: Ottawa Hospital Research Institute; 2009 [cited 12 November 2018]; Available from: http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp.
  19. Higgins JPT, Green S. Cochrane handbook for systematic reviews of interventions. Version 5.0.0. Oxford: The Cochrane Collaboration; 2008.
  20. Higgins JPT, Thompson SG, Deeks JJ, Altman D. Measuring inconsistency in meta-analyses. BMJ 2003; 327:557-60.
  21. Egger M, Davey SG, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997; 315:629-34.
  22. Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics 1994; 50:1088-101.
  23. Duval S, Tweedie R. A nonparametric "trim and fill" method of accounting for publication bias in metaanalysis. J Am Stat Assoc 2000; 95:89-98.
  24. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986; 7:177-88.
  25. Patsopoulos NA, Evangelou E, Ioannidis JP. Sensitivity of between-study heterogeneity in meta-analysis: proposed metrics and empirical evaluation. Int J Epidemiol 2008; 37:1148-57.
  26. Poorolajal J, Mahmoodi M, Majdzadeh R, Fotouhi A. MetaPlot: a novel Stata graph for assessing heterogeneity at a glance. Iran J Public Health 2010; 39:102-4.
  27. Poorolajal J, Noornejad S. Metaplot: A new Stata module for assessing heterogeneity in a meta-analysis. Plos One 2021; 16:e0253341.
  28. Goodman MT, Cologne JB, Moriwaki H, Vaeth M, Mabuchi K. Risk factors for primary breast cancer in Japan: 8-year follow-up of atomic bomb survivors. Prev Med 1997; 26:144-53.
  29. Szklo M, Nieto FJ. Epidemiology, beyond the basics. Burlington: Jones & Bartlett Learning; 2019.
  30. Poorolajal J. Equivalence model: a new graphical model for causal inference. Epidemiol Health 2020; 42:e2020024.
  31. Ambrosone CB, Kropp S, Yang J, Yao S, Shields PG, Chang-Claude J. Cigarette smoking, N-acetyltransferase 2 genotypes, and breast cancer risk: pooled analysis and meta-analysis. Cancer Epidemiol Biomarkers Prev 2008; 17:15-26.
  32. World Health Organization. World No Tobacco Day 2017: Beating tobacco for health, prosperity, the environment and national development. Geneva: WHO; 2017 [cited 1 June 2017]; Available from: http://www.who.int/mediacentre/news/releases/2017/no-tobacco-day/en/.
  33. Dyke GW, Craven JL, Hall R, Garner RC. Smoking-related DNA adducts in human gastric cancers. Int J Cancer 1992; 52:847-50.
  34. Pfeifer GP, Denissenko MF, Olivier M, Tretyakova N, Hecht SS, Hainaut P. Tobacco smoke carcinogens, DNA damage and p53 mutations in smoking-associated cancers. Oncogene 2002; 21:7435-51.
  35. Seitz HK, Stickel F. Molecular mechanisms of alcohol-mediated carcinogenesis. Nat Rev Cancer 2007; 7:599-612.
  36. Deman J, Van Larebeke N. Carcinogenesis: mutations and mutagens. Tumour Biol 2001; 22:191-202.
  37. Huh K, Kwon TH, Shin US, Kim WB, Ahn BO, Oh TY. Inhibitory effects of DA-9601 on ethanol-induced gastrohemorrhagic lesions and gastric xanthine oxidase activity in rats. J Ethnopharmacol 2003; 88:269-73.
  38. Poorolajal J, Moradi L, Mohammadi Y, Cheraghi Z, Gohari-Ensaf F. Risk factors for stomach cancer: a systematic review and meta-analysis. Epidemiol Health 2020; 42:e2020004.
  39. Key J, Hodgson S, Omar RZ, Jensen TK, Thompson SG, Boobis AR. Meta-analysis of studies of alcohol and breast cancer with consideration of the methodological issues. Cancer Causes Control 2006; 17:759-70.
  40. Bagnardi V, Rota M, Botteri E, Tramacere Tramacere, Islami F, Fedirko V. Alcohol consumption and site-specific cancer risk: a comprehensive dose–response meta-analysis. Br J Cancer 2015; 112:280-593.
  41. Jenabi E, Poorolajal J. The effect of body mass index on endometrial cancer: a meta-analysis. Public Health 2015; 129:872-80.
  42. Poorolajal J, Jenabi E. The association between BMI and cervical cancer risk: a meta-analysis. Eur J Cancer Prev 2016; 25:232-8.
  43. Poorolajal J, Jenabi E, Masoumi SZ. Body Mass Index Effects on Risk of Ovarian Cancer: A Meta-Analysis. Asian Pac J Cancer Prev 2014; 15:7665-71.
  44. Steinberg KK, Smith SJ, Thacker SB, Stroup DF. Breast cancer risk and duration of estrogen use: the role of study design in meta-analysis. Epidemiology 1994; 5:415-21.
  45. Steinberg KK, Thacker SB, Smith SJ, Stroup DF, Zack MM, Flanders WD. A meta-analysis of the effect of estrogen replacement therapy on the risk of breast cancer. JAMA 1991; 265:1985-90.
  46. Zghair AN, Sharma R, Sharma AK. Hormone responsive breast cancer and BRCA1 mutation: mechanism, regulation and iron-mediated effects. Curr Pharm Biotechnol 2014; 15:1113-24.
  47. Neubauer H, Ruan X, Schneck H, Seeger H, Cahill MA, Liang Y. Overexpression of progesterone receptor membrane component 1: possible mechanism for increased breast cancer risk with norethisterone in hormone therapy. Menopause 2013; 20:504-10.
  48. Wiebe JP, Pawlak KJ, Kwok A. Mechanism of action of the breast cancer-promoter hormone, 5alpha-dihydroprogesterone (5alphaP), involves plasma membrane-associated receptors and MAPK activation. J Steroid Biochem Mol Biol 2016; 155:166-76.
  49. Unar-Munguia M, Torres-Mejia G, Colchero MA, Gonzalez de Cosio T. Breastfeeding Mode and Risk of Breast Cancer: A Dose-Response Meta-Analysis. J Hum Lact 2017; 33:422-34.
  50. Namiranian N, Moradi-Lakeh M, Razavi-Ratki SK, Doayie M, Nojomi M. Risk factors of breast cancer in the Eastern Mediterranean Region: a systematic review and meta-analysis. Asian Pac J Cancer Prev 2014; 15:9535-41.
  51. Chakravarthi BV, Varambally S. Targeting the link between late pregnancy and breast cancer. Elife 2013; 2:e01926.
  52. Chen X, Wang Q, Zhang Y, Xie Q, Tan X. Physical Activity and Risk of Breast Cancer: A Meta-Analysis of 38 Cohort Studies in 45 Study Reports. Value Health 2019; 22:104-28.
  53. Wu Y, Zhang D, Kang S. Physical activity and risk of breast cancer: a meta-analysis of prospective studies. Breast Cancer Res Treat 2013; 137:869-82.
  54. Smallbone K, Maini PK, Gatenby RA. Episodic, transient systemic acidosis delays evolution of the malignant phenotype: Possible mechanism for cancer prevention by increased physical activity. Biol Direct 2010; 5:22.
  55. Zhang L, Huang S, Cao L, Ge M, Li Y, Shao J. Vegetable-Fruit-Soybean Dietary Pattern and Breast Cancer: A Meta-Analysis of Observational Studies. J Nutr Sci Vitaminol (Tokyo) 2019; 65:375-82.
  56. Gandini S, Merzenich H, Robertson C, Boyle P. Meta-analysis of studies on breast cancer risk and diet: the role of fruit and vegetable consumption and the intake of associated micronutrients. Eur J Cancer 2000; 36:636-46.
  57. Akyon Y. Effect of antioxidants on the immune response of Helicobacter pylori. Clin Microbiol Infect 2002; 8:438-41.
  58. Drake IM, Davies MJ, Mapstone NP, Dixon MF, Schorah CJ, White KL. Ascorbic acid may protect against human gastric cancer by scavenging mucosal oxygen radicals. Carcinogenesis 1996; 17:559-62.
  59. Farvid MS, Stern MC, Norat T, Sasazuki S, Vineis P, Weijenberg MP. Consumption of red and processed meat and breast cancer incidence: A systematic review and meta-analysis of prospective studies. Int J Cancer 2018; 143:2787-99.
  60. Guo J, Wei W, Zhan L. Red and processed meat intake and risk of breast cancer: a meta-analysis of prospective studies. Breast Cancer Res Treat 2015; 151:191-8.
  61. World Cancer Research Fund Network. Recommendations and public health and policy implications: WCRFN; 2018.
  62. World Cancer Research Fund Network. Diet, nutrition, physical activity and colorectal cancer: WCRFN; 2017.
Submitted: 01 Jun 2021
Revised: 24 Sep 2021
First published online: 20 Jul 2021
EndNote EndNote

(Enw Format - Win & Mac)

BibTeX BibTeX

(Bib Format - Win & Mac)

Bookends Bookends

(Ris Format - Mac only)

EasyBib EasyBib

(Ris Format - Win & Mac)

Medlars Medlars

(Txt Format - Win & Mac)

Mendeley Web Mendeley Web
Mendeley Mendeley

(Ris Format - Win & Mac)

Papers Papers

(Ris Format - Win & Mac)

ProCite ProCite

(Ris Format - Win & Mac)

Reference Manager Reference Manager

(Ris Format - Win only)

Refworks Refworks

(Refworks Format - Win & Mac)

Zotero Zotero

(Ris Format - FireFox Plugin)

Abstract View: 2861
PDF Download: 1556
Full Text View: 347